Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in newly diagnosed Multiple Myeloma (NDMM): analysis of vascular thrombotic events (VTEs) in the GRIFFIN study

被引：0

作者：

Sborov, Douglas ^{[1
]}

Baljevic, Muhamed ^{[2
]}

Reeves, Brandi ^{[3
]}

Laubach, Jacob ^{[4
]}

Efebera, Yvonne ^{[5
]}

Rodriguez, Cesar ^{[6
]}

Costa, Luciano ^{[7
]}

Chari, Ajai ^{[8
]}

Silbermann, Rebecca ^{[9
]}

Holstein, Sarah ^{[1
]}

Anderson, Larry D., Jr. ^{[10
]}

Kaufman, Jonathan ^{[11
]}

Shah, Nina ^{[12
]}

Pei, Huiling ^{[13
]}

Patel, Sharmila ^{[14
]}

Cortoos, Annelore ^{[14
]}

Bartlett, Blake ^{[15
]}

Vermeulen, Jessica ^{[16
]}

Lin, Thomas ^{[14
]}

Voorhees, Peter ^{[17
]}

Richardson, Paul G. ^{[4
]}

机构：

[1] Univ Utah, Sch Med, Huntsman Canc Inst, Salt Lake City, UT USA

[2] Univ Nebraska Med Ctr, Div Oncol & Hematol, Dept Internal Med, Omaha, NE USA

[3] Univ N Carolina, Chapel Hill, NC 27515 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] OhioHealth, Columbus, OH USA

[6] Mt Sinai Tisch Canc Inst, New York, NY USA

[7] Univ Alabama Birmingham, Birmingham, AL USA

[8] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA

[9] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[10] UT Southwestern Med Ctr, Simmons Comprehens Canc Ctr, Dallas, TX USA

[11] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[12] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[13] Janssen Res & Dev LLC, Titusville, NJ USA

[14] Janssen Sci Affairs LLC, Horsham, PA USA

[15] Janssen Res & Dev LLC, Raritan, NJ USA

[16] Janssen Res & Dev LLC, Leiden, Netherlands

[17] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-180

引用

页码：S135 / S136

页数：2

共 50 条

[31] Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Kumar, Shaji K.
Kapoor, Prashant
Laplant, Betsy
Phuong-Dung, Liang
Muchtar, Eli
Buadi, Francis K.
Gonsalves, Wilson I.
Malave, Gabriella C.
Vossen, Alanna M.
Dingli, David
Go, Ronald S.
Warsame, Rahma M.
Kourelis, Taxiarchis
Hwa, Yi L.
Fonder, Amie
Hobbs, Miriam A.
Lust, John A.
Lacy, Martha Q.
Dispenzieri, Angela
Hayman, Suzanne R.
Leung, Nelson
Rajkumar, S. Vincent
Gertz, Morie A.
BLOOD, 2020, 136
[32] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia
Bahlis, Nizar
Facon, Thierry
Usmani, Saad Z.
Kumar, Shaji K.
Plesner, Torben
Orlowski, Robert Z.
Touzeau, Cyrille
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael E.
Venner, Christopher P.
Weisel, Katja C.
Krevvata, Maria
Pei, Huiling
Wang, Jianping
Van Rampelbergh, Rian
Ukropec, Jon
Uhlar, Clarissa M.
Kobos, Rachel
Perrot, Aurore
BLOOD, 2019, 134
[33] Daratumumab (DARA) plus Bortezomib/Thalidomide/Dexamethasone (D-VTd) and DARA Maintenance in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): CASSIOPEIA Minimal Residual Disease (MRD) Update
Corre, Jill
Vincent, Laure
Moreau, Philippe
Hebraud, Benjamin
Hulin, Cyrille
Bene, Marie
Broijl, Annemiek
Caillot, Denis
Delforge, Michel
Dejoie, Thomas
Facon, Thierry
Lambert, Jerome
Leleu, Xavier
Macro, Margaret
Perrot, Aurore
Zweegman, Sonja
Hua, Winnie
Krevvata, Maria
Vanquickelberghe, Veronique
Tuozzo, Alba
Rowe, Melissa
Carson, Robin
Wuilleme, Soraya
Avet-Loiseau, Herve
Sonneveld, Pieter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S29 - S30
[34] Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Bhutani, Manisha
Robinson, Myra
Atrash, Shebli
Paul, Barry
Pineda-Roman, Mauricio
Foureau, David
Varga, Cindy
Friend, Reed
Begic, Xhevahire
Norek, Sarah
Drennan, Tiffany
Anderson, Michelle B.
Symanowski, James
Voorhees, Peter M.
Usmani, Saad Z.
BLOOD, 2023, 142
[35] Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
Liang, Dong
Bai, Shenrui
Feng, Demei
Chen, Guanjun
Liang, Yang
Wang, Hua
BMC CANCER, 2024, 24 (01)
[36] Isatuximab Plus Lenalidomide and Dexamethasone With Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma: The Benefit Study
Leleu, Xavier
Hulin, Cyrille
Lambert, Jerome
Bobin, Arthur
Perrot, Aurore
Manier, Salomon
Jaccard, Arnaud
Montes, Lydia
Karlin, Lionel
Godmer, Pascal
Chalopin, Thomas
Slama, Borhane
Chretien, Marie Lorraine
Laribi, Karim
Dingremont, Claire
Roul, Christophe
Mariette, Clara
Rigaudeau, Sophie
Macro, Margaret
Mohty, Mohamad
Touzeau, Cyrille
Moreau, Philippe
Avet-Loiseau, Herve
Corre, Jill
Facon, Thierry
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S33 - S33
[37] Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients
Joseph, Nisha
Gupta, Vikas A.
Hofmeister, Craig C.
Gleason, Charise
Heffner, Leonard
Boise, Lawrence H.
Kaufman, Jonathan L.
Dhodapkar, Madhav V.
Lonial, Sagar
Nooka, Ajay K.
BLOOD, 2018, 132
[38] Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
Bhutani, Manisha
Robinson, Myra
Atrash, Shebli
Watts, Nicole
Paul, Barry
Chhabra, Saurabh
Korde, Neha
Begic, Xhevahire
Foureau, David M.
Chung, David J.
Pineda-Roman, Mauricio
Koya, Brinda
Varga, Cindy
Ai, Jing
Daniels, Natonya
Norek, Sarah
Sutton, Sara A.
Anderson, Michelle B.
Jewell, Ashley N.
Eldridge, Paul W.
Acampora, Donna
Symanowski, James T.
Costa, Luciano J.
Usmani, Saad
Voorhees, Peter M.
BLOOD, 2022, 140 : 4393 - 4395
[39] Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma
Bici, Anisa
Pianko, Matthew J.
Nachar, Victoria R.
LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 407 - 414
[40] Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)
Yimer, Habte
Melear, Jason
Faber, Edward
Bensinger, William
Burke, John M.
Narang, Mohit
Stevens, Don
Gunawardena, Sriya W.
Lutska, Yana
Qi, Keqin
Ukropec, Jon
Qi, Ming
Lin, Thomas
Rifkin, Robert M.
BLOOD, 2018, 132

← 1 2 3 4 5 →